Jean Klastersky, MD, PhD of Institut Jules Bordet, Brussels, Belgium discusses adverse effects associated with immune checkpoint inhibitors. Prof Klastersky points out that adverse effects in this field are different than the adverse effects observed in classical chemotherapy, which means new challenges for cancer supportive care. Fatigue and nausea are the most common adverse effects observed. In addition, there are other complications, like colitis, pneumonitis, eye and dermatological conditions. No link between likelihood of response and the appearance of side effects has to be established so far. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.
Adverse effects of immune checkpoint inhibitors
